Authors
Latest:
Pembrolizumab/Ipilimumab Combo Effective in Advanced MelanomaA treatment regimen of pembrolizumab plus low-dose ipilimumab was tolerable and effective for patients with advanced melanoma.
Latest:
Clinical Scenario: Metastatic EBV-Positive NPCThe panel provides clinical insights on the treatment of a patient with metastatic EBV-positive nasopharyngeal carcinoma.
Latest:
The Benefits for Nurses of Using Psychosocial Cancer Registry DataRegistries, large databases of patient information collected in a systematic, standardized fashion, most often focus on biologic measures, such as pathology, radiology, and laboratory results, to track incidence and prevalence of disease as well as causative factors.
Latest:
Dr. Gitlitz Discusses the Genomics of Young Lung Cancer StudyBarbara J. Gitlitz, MD, from the University of Southern California, discusses results and key takeaways from The Genomics of Young Lung Cancer Study.
Latest:
NOW Initiative: Payer & Provider Collaborations in Oncology Benefits ManagementPayers recognize the need to expand benefits management for oncology but struggle to find effective solutions amid the complexity of available therapies and skepticism from oncologists, who are facing their own set of economic pressures. The National Oncology Working Group (NOW) Initiative is trying to change the sometimes adversarial relationship between payers and oncologists through a collaborative model.
Latest:
Data Support Safety and Benefit of Chemotherapy Before Radical CystectomyPreoperative chemotherapy was not a predictor of postoperative complications, nor did it increase the length of hospital stays or surgical complications among patients undergoing radical cystectomy for muscle-invasive bladder cancer.
Latest:
B-Cell Malignancies: Transforming Expectations and OutcomesWith the arrival and incorporation into clinical practice of immunomodulatory drugs (IMiDs) and proteasome inhibitor therapy, patients with multiple myeloma are achieving deep, durable responses and disease control, and are living longer.
Latest:
Patient-Contributed Tumor Genetics Data: A Pathway to Better Drug Development?Developing companion diagnostics has several associated challenges related to cost, access to samples, and clinical trial recruitment.
Latest:
Proving That Value-Based Care Is PossibleMore than 2 years after the passage of the Medicare Access and CHIP Reauthorization Act of 2015, the progression toward value-based care has challenged oncologists to assume an unprecedented degree of accountability for the well-being and holistic care of their patients.
Latest:
Cell Phone-based Telemonitoring Helps Cancer: Patients Adhere to Treatment RegimensWireless technologies like cell phones and radio frequency identification can help improve treatment compliance and quality of life for cancer patients.
Latest:
Dr. Paul on the Future of CAR T-Cell Therapy in Multiple Myeloma TreatmentBarry Paul, MD, discusses the emerging benefits of integrating CAR T-cell therapy into treatment paradigms for patients with relapsed/refractory multiple myeloma.
Latest:
Community Practice Provides Model for Finding New Revenue in COVID-19 EraThe coronavirus disease 2019 pandemic is highlighting how independent community oncology practices are the best source for patients to receive care close to home, while also presenting several challenges for practices and their patients.
Latest:
Dr. Berger on the Significance of the Cologuard Screening TestBarry M. Berger, MD, FACP, chief medical officer, Exact Sciences, discusses the significance and benefits of the Cologuard screening test for colorectal cancer.
Latest:
Dr. Berger on Benefits of New Screening Test for CRCBarry M. Berger, MD, FACP, chief medical officer, Exact Sciences, discusses Cologuard screening test for colorectal cancer (CRC).
Latest:
Dr. Rosenbloom on Gaucher Disease Diagnosis ChallengesDr. Barry Rosenbloom, from the Comprehensive Gaucher Treatment Center, on Gaucher Disease Diagnosis Challenges
Latest:
Advancing Prostate Cancer CareThe prostate cancer team at the Comprehensive Cancer Center at Wake Forest Baptist Medical Center has recently focused on two primary areas: minimally invasive care and clinical research.
Latest:
The Future of Chronic GvHD TreatmentExpert panelists share final thoughts concerning the future of chronic GvHD treatment, highlighting unmet needs, ongoing trials, and promising therapies.
Latest:
Dr. Scott on Conditioning Regimens for Stem Cell TransplantsBart Scott, MD, Fred Hutchinson Cancer Research Center, explains the importance of the intensity of conditioning for stem cell transplants.
Latest:
Dr. William on Brentuximab Vedotin/Lenalidomide in T-Cell LymphomaBasem William, MD, MRCP, FACP, discusses the preliminary results of the phase II trial of brentuximab vedotin and lenalidomide in relapsed/refractory cutaneous and peripheral T-cell lymphomas.
Latest:
Dr. El-Rayes on the Efficacy of Tidutamab in Advanced NETsBassel El-Rayes, MD, discusses the efficacy of tidutamab in advanced neuroendocrine tumors.
Latest:
Dr. Schilling on the Importance of Distinguishing Ocular MelanomaBastian Schilling, MD, University of Wuerzburg, discusses different types of ocular melanoma and the importance of distinguishing this subtype.
Latest:
Dr. Jagielska on Long-Term Survival With Lapatinib Plus Capecitabine in HER2+ Breast CancerBeata Jagielska, MD, PhD, internist, Centrum Medyczne Damiana Warsaw, discusses long-term survival with lapatinib (Tykerb) plus capecitabine in patients with HER2-positive breast cancer.
Latest:
CMS Should Broaden Coverage for Germline Mutation TestingSometimes referred to as massively parallel sequencing, next-generation sequencing evaluates millions of DNA sequences simultaneously, representing a true revolution compared with traditional, labor-intensive methods in which far less DNA could be sequenced at once.
Latest:
Dr. George on the Phase III TAGS Trial in Gastric/GEJ CancerBen George, MD, assistant professor, Medical College of Wisconsin, discusses the phase III TAGS trial in patients with gastric or gastroesophageal junction (GEJ) cancer.
Latest:
MedPAC's Latest Part B Proposals Would Raise the Cost of CareThe Medicare Payment Advisory Commission (MedPAC) voted to approve several proposals aimed at decreasing Medicare spending for Part B physician-administered drugs.
